ISIS Pharmaceuticals Given Average Rating of "Hold" by Analysts
Shares of ISIS Pharmaceuticals have earned a consensus rating of "Hold" from the eleven ratings firms that are covering the company, Analyst Ratings Network.com reports .
Is Biogen A Value Stock Yet?
Biogen Idec may be headquartered in Cambridge, Massachusetts, but it still has many ties to my hometown of San Diego.
Upcoming Events, Shares, Stock Price Updates, Notes Exchange Offer,...
Upcoming Events, Shares, Stock Price Updates, Notes Exchange Offer, Clinical Study Results and New Product Launch - Analyst Notes on Salix, Endo, ISIS, IDEXX, and Novo Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals, Ltd. , Endo International PLC , ISIS Pharmaceuticals, Inc. , IDEXX Laboratories, Inc. , and Novo ... (more)
ISIS Pharmaceuticals CEO Stanley T. Crooke Sells 8,800 Shares
ISIS Pharmaceuticals CEO Stanley T. Crooke sold 8,800 shares of the stock on the open market in a transaction dated Wednesday, April 2nd.
Isis Reports Positive Phase 2 Study Results For Antisense Drug
Isis Pharmaceuticals Inc. announced positive final results from the Phase II study evaluating its antisense drug ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable doses of fibrates.
"Isis Pharmaceuticals, Inc. - Strategy and SWOT Report" now available at Fast Market Research
Isis Pharmaceuticals, Inc. - Strategy and SWOT Report, is a source of comprehensive company data and information.
Thomson Reuters Announces Nominations for Top Pharma Deals of the Year
The awards -- to be determined by public vote -- will be presented , at Allicense [ http://www.allicense.com/ ], a prominent event connecting business development, licensing and M&A professionals throughout pharma, biotech and finance to discuss industry-wide challenges and collaborate on creating a roadmap for the future of pharmaceutical ... (more)
Applied Clinical Trials
Isis Reports Final Phase 2 Data On ISIS-APOCIII Rx In Patients With...
In this study, patients treated with ISIS-APOCIIIRx achieved average reductions of up to 71 percent in apolipoprotein C-III and up to 64 percent in triglycerides, and average increases of up to 52 percent in high-density lipoprotein cholesterol , the 'good' cholesterol.
"Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014" now available at Fast Market Research
This report provides information on the therapeutic development for Spinal Muscular Atrophy , complete with latest updates, and special features on late-stage and discontinued projects.
EARLIER: Isis Announces Antisense Targeting of HBV Produces...
Isis Pharmaceuticals, Inc. announced that treatment with an antisense compound targeting hepatitis B virus produced dose-dependent reductions in all measured liver and serum viral markers of HBV infection in animal models of HBV infection.